Update on pathogenesis of cystic fibrosis lung disease

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 6, 2003, Pages 486-491

  Donaldson, Scott H ^a   Boucher, Richard C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Airway surface liquid depletion; Cystic fibrosis; Mucus stasis; Pathogenesis

Indexed keywords

LUNG SURFACTANT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CELL FUNCTION; CHLORIDE TRANSPORT; COUGHING; CYSTIC FIBROSIS; GENETICS; GRAM NEGATIVE INFECTION; HUMAN; HYPOTHESIS; ION TRANSPORT; LUNG ALVEOLUS SURFACE TENSION; LUNG DISEASE; MUCUS; MUCUS SECRETION; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT MUCOSA; REVIEW; SODIUM ABSORPTION;

EID: 0142010657     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200311000-00007     Document Type: Review

References (55)

1. di Sant' Agnese PA, Darling RC, Perera GA: Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics 1953, 12:549-563.
2. Quinton PM: Chloride impermeability in cystic fibrosis. Nature 1983, 301:421-422.
3. Knowles MR, Stutts MJ, Spock A, et al.: Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983, 221:1067-1070.
4. Rommens JM, Iannuzzi MC, Kerem B, et al.: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
5. Bear CE, Li CH, Kartner N, et al.: Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992, 68:809-818.
6. Kartner N, Hanrahan JW, Jensen TJ, et al.: Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 1991, 64:681-691.
7. Stutts MJ, Rossier BC, Boucher RC: Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 1997, 272:14037-14040.
8. Stutts MJ, Canessa CM, Olsen JC, et al.: CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269:847-850.
9. Schwiebert EM, Egan ME, Hwang TH, et al.: CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995, 81:1063-1073.
10. Tarran R, Loewen ME, Paradiso AM, et al.: Regulation of murine airway surface liquid volume by CFTR and Ca2+-activated Cl- conductances. J Gen Physiol 2002, 120:407-418.
11. Bradbury NA, Jilling T, Berta G, et al.: Regulation of plasma membrane recycling by CFTR. Science 1992, 256:530-532.
12. Biwersi J, Emans N, Verkman AS: Cystic fibrosis transmembrane conductance regulator activation stimulates endosome fusion in vivo. Proc Natl Acad Sci U S A 1996, 93:12484-12489.
13. Jiang Q, Mak D, Devidas S, et al.: Cystic fibrosis transmembrane conductance regulator-associated ATP release is controlled by a chloride sensor. J Cell Biol 1998, 143:645-657.
14. Estell K, Braunstein G, Tucker T, et al.: Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ- interacting motif. Mol Cell Biol 2003, 23:594-606.
15. Zar H, Saiman L, Quittell L, et al.: Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995, 126:230-233.
16. Rhim AD, Stoykova L, Glick MC, et al.: Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell. Glycoconj J 2001, 18:649-659.
17. Scanlin TF, Glick MC: Terminal glycosylation in cystic fibrosis. Biochim Biophys Acta 1999, 1455:241-253.
18. Bryan R, Kube D, Perez A, et al.: Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am J Respir Cell Mol Biol 1998, 19:269-277.
19. Barasch J, Kiss B, Prince A, et al.: Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991, 352:70-73.
20. Pier GB, Grout M, Zaidi TS, et al.: Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996, 271:64-67.
21. Schroeder TH, Reiniger N, Meluleni G, et al.: Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol 2001, 166:7410-7418.
22. Armstrong DS, Grimwood K, Carlin JB, et al.: Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
23. Dakin CJ, Numa AH, Wang H, et al.: Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002, 165:904-910.
24. Noah TL, Black HR, Cheng PW, et al.: Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997, 175:638-647.
25. Muhlebach MS, Stewart PW, Leigh MW, et al.: Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999, 160:186-191.
26. Khan TZ, Wagener JS, Bost T, et al.: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
27. Bonfield TL, Konstan MW, Berger M: Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999, 104:72-78.
28. Matsui H, Grubb B, Tarran R, et al.: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
29. Jayaraman S, Song YL, Verkman AS: Airway surface liquid osmolality measured using fluorophore-encapsulated liposomes. J Gen Physiol 2001, 117:423-430.
30. Jayaraman S, Song YL, Vetrivel L, et al.: Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH. J Clin Invest 2001, 107:317-324.
31. Tarran R, Grubb BR, Parsons D, et al.: The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001, 8:149-158.
32. Regnis JA, Robinson M, Bailey DL, et al.: Mucociliary clearance in patients with cystic-fibrosis and in normal subjects. Am J Respir Crit Care Med 1994, 150:66-71.
33. Zuelzer WW, Newton WA Jr: The pathogenesis of fibrocystic disease of the pancreas. A study of 36 cases with special reference to the pulmonary lesions. Pediatrics 1949, 4:53-69.
34. Zabner J, Smith JJ, Karp PH, et al.: Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell 1998, 2:397-403.
35. Joris L, Dab I, Quinton PM: Elemental composition of human airway surface fluid in healthy and diseased airways. Am Rev Respir Dis 1993, 148:1633-1637.
36. Smith JJ, Travis SM, Greenberg EP, et al.: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236. [Published erratum appears in Cell 1996, 18: following 355.]
37. Goldman MJ, Anderson GM, Stolzenberg ED, et al.: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997, 88:553-560.
38. Bals R, Wang XR, Wu ZR, et al.: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998, 102:874-880.
39. Caldwell RA, Grubb BR, Tarran R, et al.: In vivo airway surface liquid Cl-analysis with solid-state electrodes. J Gen Physiol 2002, 119:3-14.
40. Matsui H, Davis CW, Tarran R, et al.: Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia [see comments]. J Clin Invest 2000, 105:1419-1427.
41. Tarran R, Grubb BR, Gatzy JT, et al.: The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001, 118:223-236.
42. Singh PK, Jia HP, Wiles K, et al.: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998, 95:14961-14966.
43. Travis SM, Conway BA, Zabner J, et al.: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999, 20:872-879.
44. Engelhardt JF, Yankaskas JR, Ernst SA, et al.: Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992, 2:240-248.
45. Sturgess J, Imrie J: Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982, 106:303-311.
46. Ballard ST, Trout L, Bebok Z, et al.: CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands. Am J Physiol 1999, 277:L694-L699.
47. Trout L, Gatzy JT, Ballard ST: Acetylcholine-induced liquid secretion by bronchial epithelium: role of Cl- and HCO3- transport. American Journal of Physiology-Lung Cellular and Molecular Physiology 1998, 19:L1095-L1099.
48. Trout L, King M, Feng W, et al.: Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. American Journal of Physiology-Lung Cellular and Molecular Physiology 1998, 18:L258-L263.
49. Inglis SK, Corboz MR, Taylor AE, et al.: Effect of anion transport inhibition on mucus secretion by airway submucosal glands. Am J Physiol 1997, 272: L372-L377.
50. Ballard ST, Trout L, Mehta A, et al.: Liquid secretion inhibitors reduce mucociliary transport in glandular airways. American Journal of Physiology-Lung Cellular and Molecular Physiology 2002, 283:L329-L335. This study provides important data linking CFTR-mediated ion transport and volume secretion in submucosal glands to mucociliary clearance in porcine airways.
51. Trout L, Townsley MI, Bowden AL, et al.: Disruptive effects of anion secretion inhibitors on airway mucus morphology in isolated perfused pig lung. Journal of Physiology-London 2003, 549:845-853. This study demonstrates the adherence of mucus plaques onto airway surfaces as the result of inhibiting anion secretion in porcine airways. The resulting experimental phenotype may recreate the early pathogenic changes in CF lung disease.
52. Jayaraman S, Joo NS, Reitz B, et al.: Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na+] and pH but elevated viscosity. Proc Natl Acad Sci U S A 2001, 98:8119-8123.
53. Joo NS, Irokawa T, Wu JV, et al.: Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem 2002, 277:50710-50715. Highlights the importance of cAMP-mediated secretion from human submucosal glands and demonstrates its absence in CF.
54. Worlitzsch D, Tarran R, Ulrich M, et al.: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325. This study describes novel CF airway environments that may predispose patients to persistent P. aeruginosa infection. The presence of anaerobic conditions within mucus plaques in CF (in vivo) is described, as well as the unique mechanisms that may create this environment in CF.
55. Yoon SS, Hennigan RF, Hilliard GM, et al.: Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002, 3:593-603. This study expands upon recent data indicating that P. aeruginosa may grow anaerobically in the CF lung. Provides data suggesting that Pseudomonas biofilms are formed more favorably under anaerobic conditions, and outlines the metabolic pathways that are utilized.